MedPath

OrsoBio, Inc.

OrsoBio, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2021-01-01
Employees
11
Market Cap
-
Website
http://orsobio.com

Clinical Trials

4

Active:1
Completed:1

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Phase 2
Recruiting
Conditions
Hypertriglyceridemia
Nonalcoholic Fatty Liver Disease
Interventions
Drug: Placebo
Drug: TLC-2716 Dose 1
Drug: TLC-2716 Dose 2
First Posted Date
2024-08-21
Last Posted Date
2025-04-03
Lead Sponsor
OrsoBio, Inc
Target Recruit Count
30
Registration Number
NCT06564584
Locations
🇲🇽

OrsoBio Research Site, Ciudad de México, Mexico

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

Phase 1
Recruiting
Conditions
Healthy Subjects
Obesity
Type 2 Diabetes
Interventions
Drug: TLC-6740 Oral Solution
Drug: TLC-6740 Tablet
Other: Placebo Oral Solution
Other: Placebo Tablet
Drug: Drug Metabolizing Enzyme
First Posted Date
2023-04-20
Last Posted Date
2025-05-23
Lead Sponsor
OrsoBio, Inc
Target Recruit Count
514
Registration Number
NCT05822544
Locations
🇳🇿

OrsoBio Reseach Site, Auckland, New Zealand

🇳🇿

OrsoBio Research Site, Christchurch, New Zealand

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Phase 2
Active, not recruiting
Conditions
Insulin Resistance
Interventions
Drug: Placebo
Drug: TLC-3595 Dose 2
Drug: TLC-3595 Dose 1
First Posted Date
2022-12-27
Last Posted Date
2024-08-20
Lead Sponsor
OrsoBio, Inc
Target Recruit Count
76
Registration Number
NCT05665751
Locations
🇳🇿

OrsoBio Research Site, Christchurch, New Zealand

🇳🇿

OrsoBio Reseach Site, Auckland, New Zealand

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Other: Placebo
First Posted Date
2022-08-02
Last Posted Date
2024-05-20
Lead Sponsor
OrsoBio, Inc
Target Recruit Count
100
Registration Number
NCT05483998
Locations
🇳🇿

OrsoBio Research Site, Auckland, New Zealand

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.